Cytotoxic T lymphocytes for leukemia and lymphoma

Hematology (United States)

Volumn 2014, Issue 1, 2014, Pages 565-569

  Bollard, Catherine M ^a   Barrett, A John ^b  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL COMMUNICATION; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LEUKEMIA; LYMPHOMA; TREATMENT OUTCOME;

CELL COMMUNICATION; HUMANS; IMMUNOTHERAPY; LEUKEMIA; LYMPHOMA; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME;

EID: 84937578269     PISSN: 15204391     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation-2014.1.565     Document Type: Article

References (37)

1. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001;411(6835):380-384.
2. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75(3):555-562.
3. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 2008;112(12):4371-4383.
4. Cohen JI. Benign and malignant Epstein-Barr virus-associated B-cell lymphoproliferative diseases. Semin Hematol. 2003;40(2):116-123.
5. Bollard CM, Rooney CM, Heslop HE. T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol. 2012; 9(9):510-519.
6. O'Reilly RJ, Lacerda JF, Lucas KG, et al. Adoptive cell therapy with donor lymphocytes for EBV-associated lymphomas developing after allogeneic marrow transplants. In: DeVita VT, Hellman S, Rosenberg SA, eds. Important Advances in Oncology 1996. Philadelphia: Lippincott-Raven; 1996;149-166.
7. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92(8941):1549-1555.
8. Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115(5):925-935.
9. Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12(10):1160-1166.
10. Young LS, Murray PG. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene. 2003;22(33):5108-5121.
11. Bollard CM, Aguilar L, Straathof KC, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus® Hodgkin's disease. J Exp Med. 2004;200(12):1623-1633.
12. Bollard CM, Gottschalk S, Leen AM, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007;110(8):2838-2845.
13. Bollard CM, Gottschalk S, Torrano V, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting epstein-barr virus latent membrane proteins. J Clin Oncol. 2014;32(8):798-808.
14. van Baarle D, Hovenkamp E, Callan MF, et al. Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma. Blood. 2001;98(1):146-155.
15. Lam S, Bollard C. T-cell therapies for HIV. Immunotherapy. 2013;5(4): 407-414.
16. Gerdemann U, Katari U, Christin AS, et al. Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Ther. 2011;19(12):2258-2268.
17. Weber G, Caruana I, Rouce RH, et al. Generation of tumor antigenspecific T cell lines from pediatric patients with acute lymphoblastic leukemia-implications for immunotherapy. Clin Cancer Res. 2013; 19(18):5079-5091.
18. Weber G, Gerdemann U, Caruana I, et al. Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant. Leukemia. 2013;27(7):1538-1547.
19. Mutis T, Brand R, Gallardo D, et al. Graft-versus-host driven graft-versusleukemia effect of minor histocompatibility antigen HA-1 in chronic myeloid leukemia patients. Leukemia. 2010;24(7):1388-1392.
20. Goulmy E. Minor histocompatibility antigens: from transplantation problems to therapy of cancer. Hum Immunol. 2006;67(6):433-438.
21. Goulmy E. Human minor histocompatibility antigens. Curr Opin Immunol. 1996;8(1):75-81.
22. Stumpf AN, van der Meijden ED, van Bergen CA, et al. Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity. Blood. 2009;114(17):3684-3692.
23. Falkenburg JH, van de Corp, Marijt EW, Willemze R. Minor histocompatibility antigens in human stem cell transplantation. Exp Hematol. 2003;31(9):743-751.
24. Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versusleukaemia effect. Nat Rev Cancer. 2004;4(5):371-380.
25. Bleakley M, Otterud BE, Richardt JL, et al. Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells. Blood. 2010;115(23):4923-4933.
26. Warren EH, Fujii N, Akatsuka Y, et al. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood. 2010;115(19):3869-3878.
27. Shafer JA, Cruz CR, Leen AM, et al. Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma. Leuk Lymphoma. 2010;51(5):870-880.
28. Cruz CR, Gerdemann U, Leen AM, et al. Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clin Cancer Res. 2011;17(22):7058-7066.
29. Bollard CM, Rossig C, Calonge MJ, et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood. 2002;99(9):3179-3187.
30. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med. 2001;7(10):1118-1122.
31. Zhang Q, Yang X, Pins M, et al. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res. 2005;65(5):1761-1769.
32. Foster AE, Dotti G, Lu A, et al. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother. 2008;31(5):500-505.
33. Dick J. Normal and leukemic human stem cells assayed in SCID mice. Semin Immunol. 1996;8(4):197-206.
34. Muranski P, Boni A, Wrzesinski C, et al. Increased intensity lymphodepletion and adoptive immunotherapy-how far can we go? Nat Clin Pract Oncol. 2006;3(12):668-681.
35. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptormodified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-1518.
36. Segler A1, Tsimberidou AM. Lenalidomide in solid tumors. Cancer Chemother Pharmacol. 2012;69(6):1393-1406.
37. Ramsay AG. Immune checkpoint blockade immunotherapy to activate anti-tumor T-cell immunity. Br J Haematol. 2013;162(3):313-325.